Insmed gave investors two reasons to cheer on Tuesday: a third-quarter loss far smaller than a year ago and higher minimum sales targets for both of its commercial products. The shares jumped 17% on the news.
The New Jersey-based biopharma reported revenue of $524.4 million for the third quarter of 2026, with $400.1 million of that coming from BRINSUPRI. The drug accounted for the bulk of quarterly sales, which helps explain why its revised outlook carried particular weight in the market’s response.
Guidance narrowed from below, not raised across the board
Insmed lifted the bottom end of its full-year BRINSUPRI revenue range to $1.35 billion from $1.25 billion, while keeping the top end at $1.40 billion. The move tightens the expected corridor upward rather than shifting the entire range higher — a distinction that matters for anyone reading the update as a straightforward upgrade.
ARIKAYCE followed the same pattern. The lower bound rose to $460 million from $450 million, with the upper end unchanged at $470 million. Both products therefore contributed to the improved minimum expectations, though the company stopped short of promising higher profits alongside the higher sales floors.
On the bottom line, the net loss fell to $100.3 million from $370.0 million in the same quarter a year earlier. Per-share losses came in at $0.46, compared with $1.75 previously. Insmed remains in the red despite the substantial improvement — a smaller shortfall is not the same as reaching breakeven.
Should investors sell immediately? Or is it worth buying Insmed?
A commercial milestone in Japan
The quarterly figures landed alongside concrete operational news. Insmed launched BRINSUPRI in Japan on October 19 as 25 mg prescription tablets for adults and children aged twelve and older with non-cystic fibrosis bronchiectasis. According to the company, it is the first approved and commercially available treatment for the condition there. The rollout, roughly two weeks old, marks a completed market entry rather than a pending announcement.
Development work on other fronts is proceeding on a separate track. At CHEST on October 15, Insmed presented its Phase 3 PALM program for treprostinil palmitil inhalation powder, or TPIP. The program spans four registration-relevant studies, three of which were already underway, covering pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, and progressive and idiopathic pulmonary fibrosis. Insmed expects PALM-IPF to begin in the first half of 2027 — a target, not a started trial.
Board additions and a busy conference calendar
The company also appointed Paul Hudson and Utpal Koppikar as independent members of its board, effective October 20. Separately, Insmed said on October 14 that it would present data from its respiratory portfolio at CHEST and IDWeek, including TPIP contributions, an ASPEN analysis of BRINSUPRI and ENCORE results on resistance development with ARIKAYCE.
Management discussed the quarter on an investor call at 8 a.m. US Eastern time. For shareholders, the takeaway is a company making commercial headway on two products and advancing a broad clinical pipeline, while still working its way toward profitability. The raised revenue floors and the narrower quarterly loss drove the reassessment; the continuing losses remain the chief caveat.
Ad
Insmed Stock: Buy or Sell?! New Insmed Analysis from October 29 delivers the answer:
The latest Insmed figures speak for themselves: Urgent action needed for Insmed investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 29.
Insmed: Buy or sell? Read more here...
